NXTC Share Price | NextCure, Inc. Stock Analysis & Recommendation

Q: What does NextCure, Inc. do?

Overview:NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)Market cap: USD 12.66 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.98Return on Equity: -88.66%Price to Book: 0.23Contact Details:Address: 9000 Virginia Manor Rd Ste 200, BELTSVILLE MD: 20705-4214Tel: 1 240 3994900Website: http://www.nextcure.com/

Q: Is NextCure, Inc. overvalued or undervalued?

As of 6 May 2021, the valuation grade for NextCure, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, primarily due to its negative financial metrics. The P/E ratio is not applicable as the company is loss-making, while the Price to Book Value stands at 0.25, and the EV to EBITDA is at 0.82. Additionally, the ROE is a concerning -88.66%, highlighting the company's struggles to generate returns.In comparison to its peers, NextCure's valuation metrics are less favorable. For instance, Rezolute, Inc. has an EV to EBITDA of -3.4613, and SELLAS Life Sciences Group, Inc. shows an EV to EBITDA of -4.5726, both indicating significant challenges in profitability. The company's recent stock performance has also been poor, with a year-to-date return of -39.04%, contrasting sharply with the S&P 500's positive return of 2.44% during the same period. This further reinforces the view that NextCure is overvalued in the current market context.

Q: Is NextCure, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for NextCure, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the weekly MACD and KST indicators, both showing mild bullishness, while the monthly RSI is bullish. However, the daily moving averages are mildly bearish, indicating some short-term weakness. The Bollinger Bands present a mixed view with a bullish weekly signal but a mildly bearish monthly signal. Overall, the indicators suggest a cautious bullish outlook.In terms of performance, NextCure has outperformed the S&P 500 over the past week and month, with returns of 3.98% and 7.54% respectively, but has significantly underperformed over longer periods, with a year-to-date return of -38.86% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

11.75 k

Shareholding (Dec 2025)

FII

2.95%

Held by 11 FIIs

DII

72.93%

Held by 7 DIIs

Promoter

17.80%

How big is NextCure, Inc.?

22-Jun-2025

As of Jun 18, NextCure, Inc. has a market capitalization of 12.66 million, with net sales of 0.00 million and a net profit of -49.52 million over the latest four quarters. Shareholder's funds are 65.47 million, and total assets are 81.92 million as of Dec 24.

View full answer

What does NextCure, Inc. do?

22-Jun-2025

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing immunomedicines for cancer and immune-related diseases, with a market cap of $12.66 million and a recent net profit of -$11 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

View full answer

Who are in the management team of NextCure, Inc.?

22-Jun-2025

As of March 2022, the management team of NextCure, Inc. includes Dr. David Kabakoff (Independent Chairman), Mr. Michael Richman (President and CEO), Dr. John Houston, Ms. Elaine Jones, Mr. Chau Khuong, Dr. Briggs Morrison, and Mr. Garry Nicholson, all serving as directors. This team oversees the company's strategic direction and operations.

View full answer

Is NextCure, Inc. overvalued or undervalued?

25-Jun-2025

NextCure, Inc. is currently considered overvalued with a valuation downgrade to "does not qualify" due to negative financial metrics, including a Price to Book Value of 0.25, an EV to EBITDA of 0.82, and a concerning ROE of -88.66%, alongside poor stock performance of -39.04% year-to-date compared to the S&P 500's positive return.

View full answer

Is NextCure, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, NextCure, Inc. has a mildly bullish trend supported by weekly indicators, despite short-term bearish signals, and has outperformed the S&P 500 recently but underperformed year-to-date.

View full answer

Compare NextCure, Inc. with Similar Stocks

Lantern Pharma, Inc.vTv Therapeutics, Inc.Bolt Biotherapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 43 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.22

Return on Equity

-245.33%

Price to Book

1.80

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.03%

6 Months

88.25%

1 Year

52.19%

2 Years

-54.34%

3 Years

546.58%

4 Years

-82.55%

5 Years

-92.43%

NextCure, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-18.03%

EBIT to Interest (avg)

-61.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.98

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

96.49%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.80

EV to EBIT

-0.23

EV to EBITDA

-0.24

EV to Capital Employed

-2.69

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-245.33%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 8 Schemes (6.33%)

Foreign Institutions

Held by 11 Foreign Institutions (2.95%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 18.97% vs 20.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.40",
          "val2": "-11.80",
          "chgp": "20.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.40",
          "val2": "-11.60",
          "chgp": "18.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -0.18% vs 11.16% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-55.40",
          "val2": "-54.30",
          "chgp": "-2.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.80",
          "val2": "-55.70",
          "chgp": "-0.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.40

-11.80

20.34%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-9.40

-11.60

18.97%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 18.97% vs 20.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-55.40

-54.30

-2.03%

Interest

0.00

Exceptional Items

0.00

-2.50

100.00%

Consolidate Net Profit

-55.80

-55.70

-0.18%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -0.18% vs 11.16% in Dec 2024

All Annual Results

Company CV

About NextCure, Inc.

NextCure, Inc.

Pharmaceuticals & Biotechnology

Nextcure Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The Company uses its functional integrated nextcure discovery in immune oncology (FIND-IO) technology to functional screening approaches for the identification of targets from multiple therapeutic areas, including autoimmunity and neurology, enabling immunomedicine to treat unmet medical needs. Its product pipelines include NC318, a immunotherapeutic against a immunomodulatory target found on a restricted set of myeloid and tumor cells, and NC410, a immunomedicine designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations.

Company Coordinates

Company Details

9000 Virginia Manor Rd Ste 200 , BELTSVILLE MD : 20705-4214

Tel: 1 240 3994900

http://www.nextcure.com/

Registrar Details